A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_7A92BC1E6EB4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Journal
Clinical lung cancer
Author(s)
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T., Araujo L.H., Saito H., Reinmuth N., Kohlmann M., Lowery C., Mann H., Peters S., Mok T.S., Johnson M.L.
ISSN
1938-0690 (Electronic)
ISSN-L
1525-7304
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Keywords
Clinical trial, Cytotoxic T-lymphocyte-associated antigen 4, Immune checkpoint inhibitor, Immunotherapy, Programmed cell death ligand-1
OAI-PMH
oai:serval.unil.ch:BIB_7A92BC1E6EB4
DOI
10.1016/j.cllc.2024.03.003
Pubmed
38584069
Open Access
Yes
Create date
12/04/2024 9:16
Last modification date
13/04/2024 7:06
Usage data